Zoldonrasib

Phase 3Small molecule

Revolution Medicines

Zoldonrasib is one of 83 small molecule programs targeting Solid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

NSCLCRecruiting

Solid TumorPreclinical

Recruiting

NSCLCPhase 3

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Zoldonrasib

Revolution Medicines

Phase 3

1 2

Nubeqa

Bayer

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Fludara

Sanofi

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 8

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Solid Tumor

NCT07397338

Q2 2030

Phase 3Recruiting

Pancreatic Cancer

NCT07805954

Phase 3Recruiting

Pancreatic Cancer

NCT07621718

Q1 2031

Phase 3Recruiting

NSCLC

NCT07777822

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07621718·670 enrolled

A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07805954·400 enrolled

NSCLC1 trial

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07777822·430 enrolled

Solid Tumor1 trial

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT07397338·370 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Zoldonrasib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zoldonrasib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zoldonrasib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revolution Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Revolution Medicines

Zoldonrasib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q2 2030

Q1 2031

Trials by Indication[1]

Pancreatic Cancer2 trials

NSCLC1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News